Cite
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status.
MLA
Facchinetti, Francesco, et al. “First-Line Pembrolizumab in Advanced Non–small Cell Lung Cancer Patients with Poor Performance Status.” European Journal of Cancer, vol. 130, May 2020, pp. 155–67. EBSCOhost, https://doi.org/10.1016/j.ejca.2020.02.023.
APA
Facchinetti, F., Mazzaschi, G., Barbieri, F., Passiglia, F., Mazzoni, F., Berardi, R., Proto, C., Cecere, F. L., Pilotto, S., Scotti, V., Rossi, S., Del Conte, A., Vita, E., Bennati, C., Ardizzoni, A., Cerea, G., Migliorino, M. R., Sala, E., Camerini, A., & Bearz, A. (2020). First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status. European Journal of Cancer, 130, 155–167. https://doi.org/10.1016/j.ejca.2020.02.023
Chicago
Facchinetti, Francesco, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, et al. 2020. “First-Line Pembrolizumab in Advanced Non–small Cell Lung Cancer Patients with Poor Performance Status.” European Journal of Cancer 130 (May): 155–67. doi:10.1016/j.ejca.2020.02.023.